What is Roth Capital’s Forecast for TENX Q1 Earnings?

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at Roth Capital issued their Q1 2025 earnings estimates for Tenax Therapeutics in a research note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff forecasts that the specialty pharmaceutical company will earn ($0.18) per share for the quarter. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($6.62) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.20) EPS.

Other equities research analysts have also recently issued research reports about the company. William Blair began coverage on Tenax Therapeutics in a research note on Monday, September 30th. They issued an “outperform” rating on the stock. Guggenheim began coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They set a “buy” rating and a $16.00 target price for the company. StockNews.com started coverage on shares of Tenax Therapeutics in a research note on Thursday, September 26th. They issued a “sell” rating on the stock. Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, October 24th. Finally, Leerink Partners initiated coverage on Tenax Therapeutics in a research report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Stock Down 1.4 %

TENX stock opened at $4.87 on Friday. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $41.92. The business has a 50-day moving average of $3.99 and a 200-day moving average of $3.70.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.99) by $0.16.

Institutional Investors Weigh In On Tenax Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Stonepine Capital Management LLC acquired a new position in Tenax Therapeutics during the third quarter worth approximately $173,000. Vestal Point Capital LP acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $288,000. Finally, Sphera Funds Management LTD. bought a new stake in Tenax Therapeutics in the 3rd quarter valued at $101,000. 1.67% of the stock is owned by institutional investors.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.